RxDoctor Payments Data

Annmarie Badagliacca

Physician Assistant · Medford, NYNPI 1982778916

Payments from drug & device makers

$4,349in general payments, 2019–2025

Across 214 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$701
  • Novo Nordisk$512
  • AstraZeneca$504
  • Lilly USA, LLC$305
  • Pfizer$259
  • Boehringer Ingelheim$248
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,337100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,349 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$82,896
Medicare patients
270
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$34,528
JardianceEmpagliflozin20$30,052
OzempicSemaglutide26$28,572
MounjaroTirzepatide12$22,297
TrulicityDulaglutide12$11,668
TradjentaLinagliptin13$11,621
Breo ElliptaFluticasone/Vilanterol11$8,171
SynthroidLevothyroxine Sodium59$2,657
Rosuvastatin Calcium168$2,370
Levothyroxine Sodium157$2,185
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$1,962
Metoprolol Succinate109$1,925
Atorvastatin Calcium189$1,663
Albuterol Sulfate HfaAlbuterol Sulfate32$1,183
Losartan Potassium121$1,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$248$41,67333 claims
PfizerEliquis$259$34,52829 claims
Lilly USA, LLCMounjaro, Trulicity$305$33,96524 claims
Novo NordiskOzempic$512$28,57226 claims
GSKBreo Ellipta$47$8,17111 claims
AbbVieSynthroid$701$2,65759 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Medford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →